DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026

Stock Information for Skye Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Skye Bioscience Inc.

Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Semtech Corporation (SMTC), Six Flags Entertainment Corporation (FUN), Skye Bioscience, Inc. (SKYE), and Stride, Inc. (LRN)
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
Skye Bioscience to Present Poster at Keystone Obesity Conference
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.